


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claim 1. (Original) Compounds of formula I



wherein

n is an integer from 1 to 4

R<sub>1</sub> is a hydrogen atom, hydroxyl group or lower C<sub>1-6</sub>alkoxy group

R<sub>2</sub> is a hydrogen atom or a straight or branched lower C<sub>1-6</sub>alkyl group

X is hydrogen, fluorine, chlorine, bromine, hydroxyl group, trifluoromethyl group, 3,4-di-Cl, 2,4-di-Cl or lower C<sub>1-6</sub> alkoxy group

and enantiomers, diastereoisomers or racemates thereof or the physiologically acceptable acid addition salts thereof.

Claim 2. (Original) The compounds according to claim 1 in which n is an integer 2, R<sub>1</sub> is a hydroxyl group, R<sub>2</sub> a methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl group and X is a hydrogen atom or phenyl disubstituted with 2 chlorine atoms in the positions 3 and 4 or in the positions 2 and 4.

Claim 3. (Currently amended) The compounds according to claims 1 and 2 in which R<sub>1</sub> is a hydroxyl group in the RS configuration.

Claim 4. (Currently amended) The compound according to claim 1 which is 1-(3-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)ethyl)-N-propylamino)ethanol and a dihydrobromide salt thereof.

Claim 5. (Currently amended) The compound according to claim 1 which is 1-(3-pyridyl)-2-(N-(2-phenylethyl)-N-propylamino)ethanol and a dihydrobromide salt thereof.

Claim 6. (Currently amended) The compound according to claim 1 which is 1-(3-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)ethyl)-N-methylamino)ethanol and a dihydrobromide salt thereof.

Claim 7. (Currently amended) The compound according to claim 1 which is 1-(4-pyridyl)-2-(N-(2-(3,4-dichlorophenyl)-N-methylamino)ethanol and a dihydrobromide salt thereof.

Claim 8. (Currently amended) The compounds of formula I according to ~~any of claims 1 to 7~~ and the physiologically acceptable acid addition salts thereof as the ligands of sigma receptors for inhibiting cholesterol biosynthesis in the treatment of hypercholesterolemia and hyperlipemia in humans.

Claim 9. (Currently amended) The pharmaceutical compositions comprising the compound of formula I according to ~~any of claims 1 to 7~~ and the physiologically acceptable acid addition salts thereof.

Claim 10. (Currently amended) Use of the compounds of formula I according to ~~any~~ claims 1 to 7 and the physiologically acceptable acid addition salts thereof as the ligands of sigma receptors for inhibiting cholesterol biosynthesis for the preparation of the pharmaceutical compositions for treating hypercholesterolemia and hyperlipemia.


Claim 11. (Currently amended) The process for preparation of the compounds of formula I according to ~~any of claims 1 to 7~~ which process comprises

a) alkylating secondary amines of formula VI




wherein

R<sub>2</sub> is as defined above in formula I and Z is a group



in which X is as defined above in formula I,

with pyridyloxirane of formula VII




and, if desired, the obtained compounds of formula I are converted into the salt or

b) alkylating primary amines of formula VIII




wherein R<sub>2</sub> is as defined above in formula I,

with pyridyloxirane of formula VII



to intermediate compounds of formula IX




wherein  $R_2$  is as defined above in formula I,

and condensing with the derivatives of phenylacetic acid of formula X



wherein Z is as defined above,

to intermediate compounds of formula XI



and reducing them to the title compounds of formula I, and, if desired, converting them into the salt.